New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis.
Twenty years of global polio eradication efforts may soon eliminate the transmission of wild-type poliovirus. However, new information that has been learned about poliovirus, as well as the political realities of a modern world, demand that universal immunity against poliomyelitis be maintained, even after wild-type poliovirus is eradicated. Although 2 excellent vaccines have proven to be highly effective in the past, neither the live-attenuated vaccine nor the currently used inactivated vaccine are optimal for use in the posteradication era. Therefore, concerted efforts are urgently needed to develop a new generation of vaccine that is risk-free and affordable and can be produced on a global scale. Here, we discuss the desired properties of a vaccine and methods to create a new polio vaccine.
Chumakov
Konstantin
K
Center for Biologics Evaluation and Research, US Food and Drug Administration, Rockville, Maryland 20852, USA. konstantin.chumakov@fda.hhs.gov
Ehrenfeld
Ellie
E
D006801:Humans; D011051:Poliomyelitis / Q000517:prevention & control*; D011054:Poliovirus Vaccine, Inactivated / Q000276:immunology*
D011054:Poliovirus Vaccine, Inactivated